secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001193125-25-312972
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo reports mipletamig 93% ORR, zero CRS in frontline AML Phase 1b/2 trial at ASH 2025
--------------------------------------------------------------------------------

- 100% of patients free of cytokine release syndrome (CRS) across cohorts 1-3.
- 93% overall response rate (ORR) among evaluable patients; 87% CR/CRi, 73% CR.
- 60% of MRD-evaluable CR/CRi patients achieved MRD-negative status; 43% of ORR patients had TP53 mutation.
- Median patient age 75; triplet regimen (mipletamig + AZA/VEN) generally well tolerated.
- Data presented Dec 8 at ASH 2025; RAINIER trial continues enrollment at additional dose levels.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312525312972/0001193125-25-312972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312525312972/apvo-20251209.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-312972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer